MX337059B - Metodos y composiciones para modular la hemostasia. - Google Patents

Metodos y composiciones para modular la hemostasia.

Info

Publication number
MX337059B
MX337059B MX2012006837A MX2012006837A MX337059B MX 337059 B MX337059 B MX 337059B MX 2012006837 A MX2012006837 A MX 2012006837A MX 2012006837 A MX2012006837 A MX 2012006837A MX 337059 B MX337059 B MX 337059B
Authority
MX
Mexico
Prior art keywords
methods
hemostasia
modulate
compositions
variants
Prior art date
Application number
MX2012006837A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MX337059B publication Critical patent/MX337059B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una variante del Factor Xa que modula la hemostasis que comprende al menos una mutación por substitución den los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde la Val en la posición 236 se sustituye con un aminoácido en la posición 235 no es Val o Ala.
MX2012006837A 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia. MX337059B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
MX337059B true MX337059B (es) 2016-02-09

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.

Country Status (25)

Country Link
US (4) US8383386B2 (es)
EP (4) EP1948690B1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR20160029135A (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2629491C (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2496567T3 (es)
GT (1) GT200800065A (es)
IL (1) IL191310A (es)
MX (3) MX336958B (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
JP6514893B2 (ja) 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
KR102049900B1 (ko) 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
CN112195169A (zh) * 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
US20160235824A1 (en) * 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
CN105934250A (zh) 2014-01-24 2016-09-07 辉瑞公司 治疗脑内出血的组合物和方法
NZ727444A (en) * 2014-05-26 2021-12-24 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
WO2016028872A2 (en) 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
WO2018022844A2 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
JP5833448B2 (ja) * 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用

Also Published As

Publication number Publication date
US8383386B2 (en) 2013-02-26
CR9956A (es) 2008-08-21
EP1948690A2 (en) 2008-07-30
US20180251745A1 (en) 2018-09-06
KR101574042B1 (ko) 2015-12-03
HK1128699A1 (en) 2009-11-06
IL191310A (en) 2015-06-30
JP5957167B2 (ja) 2016-07-27
CN101356192B (zh) 2013-09-11
MY162181A (en) 2017-05-31
RU2570547C2 (ru) 2015-12-10
RU2011130932A (ru) 2013-01-27
EP2431390B1 (en) 2015-08-12
NO20200670A1 (no) 2008-07-30
MX336958B (es) 2016-02-05
KR101600158B1 (ko) 2016-03-08
GT200800065A (es) 2008-11-03
JP2009515559A (ja) 2009-04-16
NO345177B1 (no) 2020-10-26
CA2971971A1 (en) 2007-05-24
DK1948690T3 (da) 2014-09-01
JP6571735B2 (ja) 2019-09-04
HK1165444A1 (en) 2012-10-05
MX2008006313A (es) 2008-11-06
US20160362673A1 (en) 2016-12-15
BRPI0618654B1 (pt) 2021-10-19
WO2007059513A3 (en) 2007-11-29
US9896676B2 (en) 2018-02-20
NZ568108A (en) 2011-09-30
JP2014073127A (ja) 2014-04-24
KR20140115374A (ko) 2014-09-30
US20090175931A1 (en) 2009-07-09
ES2496567T3 (es) 2014-09-19
ES2549929T3 (es) 2015-11-03
BRPI0618654A8 (pt) 2019-01-15
PT1948690E (pt) 2014-09-08
EP1948690B1 (en) 2014-06-11
SI1948690T1 (sl) 2014-09-30
ECSP088452A (es) 2008-07-30
JP2018033459A (ja) 2018-03-08
KR20160029135A (ko) 2016-03-14
AU2006315175A1 (en) 2007-05-24
KR20140005383A (ko) 2014-01-14
EP2431390A1 (en) 2012-03-21
US9410137B2 (en) 2016-08-09
AU2006315175B2 (en) 2013-02-07
ZA200804026B (en) 2009-10-28
CA2629491A1 (en) 2007-05-24
KR101827569B1 (ko) 2018-02-09
BRPI0618654A2 (pt) 2011-09-06
JP5823088B2 (ja) 2015-11-25
CN101356192A (zh) 2009-01-28
RU2008123398A (ru) 2009-12-27
KR20080078664A (ko) 2008-08-27
SV2008002906A (es) 2008-10-22
NO20082182L (no) 2008-07-30
EP2423224A1 (en) 2012-02-29
EP1948690A4 (en) 2009-06-17
EP2423224B1 (en) 2015-08-12
NO20200671A1 (no) 2008-07-30
EP2431389A1 (en) 2012-03-21
JP2016005464A (ja) 2016-01-14
WO2007059513A2 (en) 2007-05-24
CA2629491C (en) 2019-05-07
JP6236194B2 (ja) 2017-11-22
US20140120155A1 (en) 2014-05-01
PL1948690T3 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
CR9956A (es) Metodos y composiciones para modular la hemostasia
CR10213A (es) Moduladores de la proteína quinasa aurora
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NO20092637L (no) Fremgangsmater for behandling
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
NO20071127L (no) Triazoloftalaziner
DE602008000754D1 (de) Tropanverbindungen
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
PL2963031T3 (pl) Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
EA200802008A1 (ru) Фармацевтические композиции
SV2009003434A (es) Inhibicion de arni de expresion de alfa-enac
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
EA201100037A1 (ru) Органические соединения
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
PL2214656T3 (pl) Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
DE602005007237D1 (de) Haarpflegezusammensetzungen
EA200870515A1 (ru) Моноциклические гетероарильные соединения
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
EP1951050A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD